Maxacalcitol is a possible less phosphatemic vitamin D analog

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 4, 2005, Pages 352-354

  Kazama, Junichiro J ^a   Maruyama, Hiroki ^a   Narita, Ichiei ^a   Gejyo, Fumitake ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Calcitriol; Maxacalcitol; Phosphate; Secondary hyperparathyroidism

Indexed keywords

22 OXACALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

EID: 29144517794     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2005.00296.x     Document Type: Article

References (14)

1. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641-9.
2. NKF/K/DOQI. Clinical Practice Guidelines for bone mineral metabolism and disease in Chronic Kidney Disease. Am J Kid Dis 2003;42:S7-201.
3. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56.
4. Coburn JW, Maung HM, Elangovan L et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43:877-90.
5. Nishii Y, Okano T. History of the development of new vitamin D analogs: studies on 22-oxacalcitriol (OCT) and 2beta-(3-hydroxypropoxy) calcitriol (ED-71). Steroids 2001;66:137-46.
6. Brown AJ, Ritter CR, Finch JL et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989;84:728-32.
7. Finch JL, Brown AJ, Kubodera N et al. Differential effects of 1,25-(OH) 2D3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 1993;43:561-6.
8. Akizawa T, Suzuki M, Akiba T et al. Long-term effect of 1,25-dihydroxy-22-oxavitamin D (3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant 2002;17:28-36.
9. Tsukamoto Y, Hanaoka M, Matsuo T et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000;35:458-64.
10. Kazama JJ, Omori K, Higuchi N et al. Intact PTH assay overestimates 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Nephrol Dial Transp 2004;19:892-7.
11. Doi S, Yorioka N, Usui K et al. Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients. Intern Med 2003;42:955-9.
12. Yasuda M, Akiba T, Nihei H. Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients. Am J Kidney Dis 2003;41:S108-S111.
13. Oyama Y, Kazama JJ, Omori K et al. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol (in press).
14. Hirata M, Katsumata K, Endo K et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25 (OH) 2 vitamin D3. Nephrol Dial Transp. 2003;18:1770-6.